The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE)
The DEVOTE Programme accelerates genomic testing innovation by bridging discovery and clinical use. It advances rapid genetic diagnostics for strokes, antibiotic guidance, and pharmacogenetics, enhancing patient care through industry-academic-healthcare collaboration.
Project Overview
The DEVOTE programme is a collaborative initiative between industry, universities, and healthcare professionals aimed at accelerating the development and implementation of time-critical genomic testing technologies. The focus is on biomarkers, particularly genetic ones, which can be used to diagnose diseases or predict treatment outcomes.
The challenge is that there’s a significant gap between the discovery of these biomarkers and their practical use in clinical settings. Traditional genetic tests are slow, hindering their application in day-to-day patient care. The DEVOTE programme seeks to address this by fostering collaboration and supporting the development of innovative technologies.
Three exemplar projects have been selected to demonstrate the programme’s value: a rapid genetic test for stroke patients, an ultra-rapid test for guiding antibiotic therapy, and a comprehensive pharmacogenetic testing panel with an informatic solution.